Literature DB >> 22418972

[Response criteria for malignant lymphoma].

M K Ganten1.   

Abstract

CLINICAL/METHODICAL ISSUE: A proven criterion for assessing tumor response is the increase in tumor size. Unlike most tumors, lymph nodes are normal anatomical structures and can be measured even when benign. The International Working Group (IWG) criteria for lymphomas therefore combine morphological with functional (positron emission tomography PET) and biopsy (bone marrow biopsy) parameters. The IWG criteria have been established as the standard in clinical trials and take nodal involvement, spleen, liver involvement as well as bone marrow involvement into account, which makes the response evaluation complex. STANDARD RADIOLOGICAL
METHODS: This involves an investigator-dependent, non-standardized and poorly reproducible estimation of tumor response to therapy. METHODICAL INNOVATIONS: The formulation of standardized response categories for malignant lymphomas. PERFORMANCE: The aim was to produce uniform and standardized criteria for application in medication studies. ACHIEVEMENTS: Established as the standard for medication studies but too time-consuming for practical application. PRACTICAL RECOMMENDATIONS: An improved practicability can be achieved by incorporating a computer-assisted evaluation program.

Entities:  

Mesh:

Year:  2012        PMID: 22418972     DOI: 10.1007/s00117-011-2256-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  11 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 3.  [CT staging of malignant lymphoma. How to avoid misinterpretations].

Authors:  C Dechow; G Nöldge; M Libicher; G M Richter
Journal:  Radiologe       Date:  2002-12       Impact factor: 0.635

Review 4.  [Radiological evaluation of tumor response in oncological studies (tumor response evaluation)].

Authors:  B Gebauer; O Bohnsack; H Riess
Journal:  Rofo       Date:  2011-03-09

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Post-therapy CT-detected mass in lymphoma patients: is it viable tissue?

Authors:  E Lewis; M E Bernardino; P G Salvador; F F Cabanillas; P A Barnes; J L Thomas
Journal:  J Comput Assist Tomogr       Date:  1982-08       Impact factor: 1.826

7.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.

Authors:  J S Newman; I R Francis; M S Kaminski; R L Wahl
Journal:  Radiology       Date:  1994-01       Impact factor: 11.105

8.  Abdominal lymphadenopathy: spectrum of CT findings.

Authors:  D M Einstein; A A Singer; W A Chilcote; R K Desai
Journal:  Radiographics       Date:  1991-05       Impact factor: 5.333

Review 9.  [Cellular mechanisms of tumor response: clinical demands].

Authors:  M-K Ganten; M A Weber; T M Ganten
Journal:  Radiologe       Date:  2008-09       Impact factor: 0.635

Review 10.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.